ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Analyst Ratings
USA - NASDAQ:ALNY - US02043Q1076 - Common Stock
460.54 USD
+11.38 (+2.53%)
460.54 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 79% to ALNY. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 466.31. This target is 1.25% above the current price.
ALNY was analyzed by 36 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about ALNY.
In the previous month the buy percentage consensus was at a similar level.
ALNY was analyzed by 36 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-11 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-31 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-31 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-10-30 | Jefferies | Maintains | Buy -> Buy |
| 2025-10-17 | Truist Securities | Maintains | Buy -> Buy |
| 2025-10-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-06 | Stifel | Maintains | Buy -> Buy |
| 2025-10-06 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-19 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-09-17 | B of A Securities | Maintains | Buy -> Buy |
| 2025-09-16 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-09-11 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-08 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-09-02 | Citigroup | Maintains | Buy -> Buy |
| 2025-09-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-04 | Wolfe Research | Upgrade | Underperform -> Peer Perform |
| 2025-08-04 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-08-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-01 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-08-01 | UBS | Maintains | Buy -> Buy |
| 2025-08-01 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-01 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-01 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-08-01 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-01 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-01 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-07-31 | Needham | Maintains | Buy -> Buy |
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
Can you provide the average price target for ALNYLAM PHARMACEUTICALS INC stock?
36 analysts have analysed ALNY and the average price target is 466.31 USD. This implies a price increase of 1.25% is expected in the next year compared to the current price of 460.54.
What is the consensus rating for ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
The consensus rating for ALNYLAM PHARMACEUTICALS INC (ALNY) is 79.4444 / 100 . This indicates that analysts generally have a positive outlook on the stock.